105 related articles for article (PubMed ID: 17318948)
1. How to make the best use of limited resources in breast cancer treatment--experiences in Bosnia & Herzegovina.
Obralić N; Beslija S
J BUON; 2006; 11(1):21-9. PubMed ID: 17318948
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer in limited-resource countries: treatment and allocation of resources.
Eniu A; Carlson RW; Aziz Z; Bines J; Hortobágyi GN; Bese NS; Love RR; Vikram B; Kurkure A; Anderson BO;
Breast J; 2006; 12 Suppl 1():S38-53. PubMed ID: 16430398
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.
Anderson BO; Shyyan R; Eniu A; Smith RA; Yip CH; Bese NS; Chow LW; Masood S; Ramsey SD; Carlson RW
Breast J; 2006; 12 Suppl 1():S3-15. PubMed ID: 16430397
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
6. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362
[TBL] [Abstract][Full Text] [Related]
8. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
9. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer in limited-resource countries: health care systems and public policy.
Anderson BO; Yip CH; Ramsey SD; Bengoa R; Braun S; Fitch M; Groot M; Sancho-Garnier H; Tsu VD;
Breast J; 2006; 12 Suppl 1():S54-69. PubMed ID: 16430399
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer in the elderly.
Crivellari D; Aapro M; Leonard R; von Minckwitz G; Brain E; Goldhirsch A; Veronesi A; Muss H
J Clin Oncol; 2007 May; 25(14):1882-90. PubMed ID: 17488987
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
14. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study.
Shih YC; Xu Y; Cormier JN; Giordano S; Ridner SH; Buchholz TA; Perkins GH; Elting LS
J Clin Oncol; 2009 Apr; 27(12):2007-14. PubMed ID: 19289624
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Tzaida O; Gogas H; Dafni U; Kyroudi A; Papaspyrou I; Kyriakou V; Malamou-Mitsi V; Alamani M; Skopa C; Kostopoulos I; Kastritis E; Pectasides D; Briasoulis E; Kalofonos HP; Aravantinos G; Fountzilas G; Arapantoni-Dadioti P
Oncology; 2007; 72(5-6):388-96. PubMed ID: 18187961
[TBL] [Abstract][Full Text] [Related]
16. Ovarian function and childbearing issues in breast cancer survivors.
Gadducci A; Cosio S; Genazzani AR
Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
[TBL] [Abstract][Full Text] [Related]
17. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
Kahán Z; Spanik S; Wagnerova M; Skacel T; Planko B; Fitzthum E; Lindner E; Soldatenkova V; Zielinski CC; Brodowicz T
Breast Cancer Res Treat; 2008 Dec; 112(3):557-63. PubMed ID: 18189160
[TBL] [Abstract][Full Text] [Related]
20. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
